四川百利天恒获1.8亿元股票回购专项贷款承诺 资金用于员工持股或股权激励

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has obtained a loan commitment of up to 180 million RMB from Bank of China Sichuan Branch to support its share repurchase plan [1][3]. Group 1: Share Repurchase Plan - The company approved a share repurchase plan on December 30, 2025, intending to use self-owned and/or self-raised funds to repurchase A-shares through centralized bidding, with a total repurchase amount between 100 million RMB and 200 million RMB, and a maximum repurchase price of 546 RMB per share [2]. - The repurchase period is set for 12 months from the date of the board's approval, with the repurchased shares planned for future employee stock ownership plans or equity incentives [2]. Group 2: Loan Commitment Details - The loan commitment specifies that the funds are to be used exclusively for the repurchase of company shares, with a loan term of three years [3]. - The actual details of the loan will be formalized in a stock repurchase loan contract between the company and the bank [3]. Group 3: Additional Notes - The loan commitment enhances the flexibility of the company's repurchase funds and reflects the financial institution's recognition of the company's growth prospects [4]. - The company clarifies that the loan does not guarantee the total repurchase amount, and the actual number of shares repurchased will depend on market conditions and fund availability [4].